Skip to main content
Top
Published in: The Patient - Patient-Centered Outcomes Research 2/2010

01-06-2010 | Original Research Article

Assessing Drug Treatment Preferences of Patients with Crohn’s Disease

A Conjoint Analysis

Authors: Dr Gary R. Lichtenstein, Heidi C. Waters, Jenna Kelly, Susan S. McDonald, Elaine L. Zanutto, David Hendricks, Mirza I. Rahman

Published in: The Patient - Patient-Centered Outcomes Research | Issue 2/2010

Login to get access

Abstract

Background: Patient preference has been recognized as being of increasing importance when choosing a drug therapy for chronic conditions for which there are no cures and for which long-term treatment is needed.
Objective: To quantify treatment preferences and priorities of patients with Crohn’s disease (CD).
Methods: This was a prospective Internet-based survey of adult participants with moderate to severe CD who were recruited through two national survey panels in the US. The survey included questions about diagnostic and treatment histories, attitudes and perceptions related to CD, and CD therapy. In a discrete-choice-based conjoint exercise, respondents selected a preferred biologic treatment option from each of 16 pairs of drug profiles that systematically varied efficacy, convenience, and product history attributes. A hierarchical Bayes probit model was utilized to estimate respondent-level ‘utility scores’ for each of the attribute levels. In a separate exercise, respondents also directly ranked each specific attribute. Two-tailed tests were conducted to determine statistical significance at p < 0.05.
Results: A total of 252 participants were surveyed, 202 (80%) of whom were biologic naive. Mean age was 44.1 years and mean disease duration was 11.6 years. The majority (71.8%) were female. In the conjoint exercise, the three attributes of greatest importance in accounting for patients’ biologic therapy preference were (greater) proportion of patients achieving lasting remission, (decreased) frequency of medication administration, and (higher) proportion of patients responding in 2 weeks. In the direct ranking exercise, the proportion of CD patients achieving lasting remission was selected as the most important attribute by the most respondents (27%), followed by the proportion of CD patients responding in 2 weeks (23%).
Conclusion: Achievement of lasting remission and a rapid clinical response were the biologic treatment characteristics highly valued by respondents in this survey. It is critical that physicians provide patients with balanced information regarding the benefits and risks, convenience, and medication history of each treatment option available to them in order for patients to make informed therapy choices that reflect their personal priorities.
Literature
1.
go back to reference Loftus Jr EV, Schoenfeld P, Sandborn WJ. The epidemiology and natural history of Crohn’s disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther 2002; 16(1): 51–60PubMedCrossRef Loftus Jr EV, Schoenfeld P, Sandborn WJ. The epidemiology and natural history of Crohn’s disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther 2002; 16(1): 51–60PubMedCrossRef
2.
go back to reference Loftus Jr EV, Silverstein MD, Sandborn WJ, et al. Crohn’s disease in Olmsted County, Minnesota, 1940–1993: incidence, prevalence, and survival. Gastroenterology 1998; 114(6): 1161–8PubMedCrossRef Loftus Jr EV, Silverstein MD, Sandborn WJ, et al. Crohn’s disease in Olmsted County, Minnesota, 1940–1993: incidence, prevalence, and survival. Gastroenterology 1998; 114(6): 1161–8PubMedCrossRef
3.
go back to reference Weinberger M, Oddone EZ, Henderson WG. Does increased access to primary care reduce hospital readmissions? Veterans Affairs Cooperative Study Group on Primary Care and Hospital Readmission. N Engl J Med 1996; 334(22): 1441–7PubMedCrossRef Weinberger M, Oddone EZ, Henderson WG. Does increased access to primary care reduce hospital readmissions? Veterans Affairs Cooperative Study Group on Primary Care and Hospital Readmission. N Engl J Med 1996; 334(22): 1441–7PubMedCrossRef
4.
go back to reference Garcia Popa-Lisseanu MG, Greisinger A, Richardson M, et al. Determinants of treatment adherence in ethnically diverse, economically disadvantaged patients with rheumatic disease. J Rheumatol 2005; 32(5): 913–9 Garcia Popa-Lisseanu MG, Greisinger A, Richardson M, et al. Determinants of treatment adherence in ethnically diverse, economically disadvantaged patients with rheumatic disease. J Rheumatol 2005; 32(5): 913–9
5.
go back to reference Sherbourne CD, Hays RD, Ordway L, et al. Antecedents of adherence to medical recommendations: results from the Medical Outcomes Study. J Behav Med 1992; 15(5): 447–68PubMedCrossRef Sherbourne CD, Hays RD, Ordway L, et al. Antecedents of adherence to medical recommendations: results from the Medical Outcomes Study. J Behav Med 1992; 15(5): 447–68PubMedCrossRef
6.
go back to reference Johnson FR, Ozdemir S, Mansfield C, et al. Crohn’s disease patients’ risk-benefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology 2007; 133(3): 769–79PubMedCrossRef Johnson FR, Ozdemir S, Mansfield C, et al. Crohn’s disease patients’ risk-benefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology 2007; 133(3): 769–79PubMedCrossRef
7.
go back to reference Johnson FR, Ozdemir S, Mansfield C, et al. Are adult patients more tolerant of treatment risks than parents of juvenile patients? Risk Anal 2009; 29(1): 121–36PubMedCrossRef Johnson FR, Ozdemir S, Mansfield C, et al. Are adult patients more tolerant of treatment risks than parents of juvenile patients? Risk Anal 2009; 29(1): 121–36PubMedCrossRef
8.
go back to reference Hauber AB, Johnson FR, Sauriol L, et al. Risking health to avoid injections: preferences of Canadians with type 2 diabetes. Diabetes Care 2005; 28(9): 2243–5PubMedCrossRef Hauber AB, Johnson FR, Sauriol L, et al. Risking health to avoid injections: preferences of Canadians with type 2 diabetes. Diabetes Care 2005; 28(9): 2243–5PubMedCrossRef
9.
go back to reference Hunt LM, Valenzuela MA, Pugh JA. NIDDM patients’ fears and hopes about insulin therapy: the basis of patient reluctance. Diabetes Care 1997; 20(3): 292–8PubMedCrossRef Hunt LM, Valenzuela MA, Pugh JA. NIDDM patients’ fears and hopes about insulin therapy: the basis of patient reluctance. Diabetes Care 1997; 20(3): 292–8PubMedCrossRef
10.
go back to reference Sandborn WJ, Feagan BG, Lichtenstein GR. Medical management of mild to moderate Crohn’s disease: evidence-based treatment algorithms for induction and maintenance of remission. Aliment Pharmacol Ther 2007; 26(7): 987–1003PubMedCrossRef Sandborn WJ, Feagan BG, Lichtenstein GR. Medical management of mild to moderate Crohn’s disease: evidence-based treatment algorithms for induction and maintenance of remission. Aliment Pharmacol Ther 2007; 26(7): 987–1003PubMedCrossRef
11.
go back to reference Munkholm P, Langholz E, Davidsen M, et al. Frequency of glucocorticoid resistance and dependency in Crohn’s disease. Gut 1994; 35(3): 360–2PubMedCrossRef Munkholm P, Langholz E, Davidsen M, et al. Frequency of glucocorticoid resistance and dependency in Crohn’s disease. Gut 1994; 35(3): 360–2PubMedCrossRef
12.
go back to reference Steinhart H. Maintenance therapy in Crohn’s disease. Can J Gastroenterol 2000; 14Suppl. C: 23–8C Steinhart H. Maintenance therapy in Crohn’s disease. Can J Gastroenterol 2000; 14Suppl. C: 23–8C
13.
go back to reference Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn’s disease with 6-mercaptopurine: a long-term, randomized, double-blind study. N Engl J Med 1980; 302(18): 981–7PubMedCrossRef Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn’s disease with 6-mercaptopurine: a long-term, randomized, double-blind study. N Engl J Med 1980; 302(18): 981–7PubMedCrossRef
14.
go back to reference Remicade: package insert. Malvern (PA): Centocor, Inc., 2007 Remicade: package insert. Malvern (PA): Centocor, Inc., 2007
15.
go back to reference 15. Humira: package insert. Abbott Park (IL): Abbott Laboratories, 2006 15. Humira: package insert. Abbott Park (IL): Abbott Laboratories, 2006
16.
go back to reference Cross RK, Lapshin O, Finkelstein J. Patient subjective assessment of drug side effects in inflammatory bowel disease. J Clin Gastroenterol 2008; 42(3): 244–51PubMed Cross RK, Lapshin O, Finkelstein J. Patient subjective assessment of drug side effects in inflammatory bowel disease. J Clin Gastroenterol 2008; 42(3): 244–51PubMed
17.
go back to reference Eisen GM, Locke III GR, Provenzale D. Health-related quality of life: a primer for gastroenterologists. Am J Gastroenterol 1999; 94(8): 2017–21PubMedCrossRef Eisen GM, Locke III GR, Provenzale D. Health-related quality of life: a primer for gastroenterologists. Am J Gastroenterol 1999; 94(8): 2017–21PubMedCrossRef
18.
go back to reference Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2006; 23(5): 577–85PubMedCrossRef Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2006; 23(5): 577–85PubMedCrossRef
19.
go back to reference Ediger JP, Walker JR, Graff L, et al. Predictors of medication adherence in inflammatory bowel disease. Am J Gastroenterol 2007; 102(7): 1417–26PubMedCrossRef Ediger JP, Walker JR, Graff L, et al. Predictors of medication adherence in inflammatory bowel disease. Am J Gastroenterol 2007; 102(7): 1417–26PubMedCrossRef
20.
go back to reference Kane SV. Strategies to improve adherence and outcomes in patients with ulcerative colitis. Drugs 2008; 68(18): 2601–9PubMedCrossRef Kane SV. Strategies to improve adherence and outcomes in patients with ulcerative colitis. Drugs 2008; 68(18): 2601–9PubMedCrossRef
21.
go back to reference Cohen RD. The quality of life in patients with Crohn’s disease. Aliment Pharmacol Ther 2002; 16(9): 1603–9PubMedCrossRef Cohen RD. The quality of life in patients with Crohn’s disease. Aliment Pharmacol Ther 2002; 16(9): 1603–9PubMedCrossRef
22.
go back to reference Green PE, Srinivasan V. Conjoint analysis in marketing: new developments with implications for research and practice. J Marketing 1990; 54: 3–19CrossRef Green PE, Srinivasan V. Conjoint analysis in marketing: new developments with implications for research and practice. J Marketing 1990; 54: 3–19CrossRef
23.
go back to reference Blankenship AB, Breen BE, Dutka AF. State of the art marketing research. Chicago (IL): NTC Business Books, 1998 Blankenship AB, Breen BE, Dutka AF. State of the art marketing research. Chicago (IL): NTC Business Books, 1998
24.
go back to reference Orme BK. Helping managers understand the value of conjoint analysis. In: Orme BK. Getting started with conjoint analysis: strategies for product design and pricing research. Madison (WI): Research Publishers, LLC, 2006: 17–24 Orme BK. Helping managers understand the value of conjoint analysis. In: Orme BK. Getting started with conjoint analysis: strategies for product design and pricing research. Madison (WI): Research Publishers, LLC, 2006: 17–24
25.
go back to reference Kuhfeld WF. Marketing research methods in SAS: experimental design, choice, conjoint, and graphical techniques. Cary (NC): SAS Institute, Inc., 2005 Kuhfeld WF. Marketing research methods in SAS: experimental design, choice, conjoint, and graphical techniques. Cary (NC): SAS Institute, Inc., 2005
26.
go back to reference Zwerina K, Huber J, Kuhfeld WF. A general method for constructing efficient choice designs. Cary (NC): SAS Institute, Inc., 1996 Zwerina K, Huber J, Kuhfeld WF. A general method for constructing efficient choice designs. Cary (NC): SAS Institute, Inc., 1996
27.
go back to reference Rossi PE, Gilula Z, Allenby GM. Overcoming scale usage heterogeneity: a Bayesian hierarchical approach. J Am Stat Assoc 2001; 96: 20–31CrossRef Rossi PE, Gilula Z, Allenby GM. Overcoming scale usage heterogeneity: a Bayesian hierarchical approach. J Am Stat Assoc 2001; 96: 20–31CrossRef
28.
go back to reference Allenby GM, Rossi PE. Marketing models of consumer heterogeneity. J Economet 1999; 18: 57–78 Allenby GM, Rossi PE. Marketing models of consumer heterogeneity. J Economet 1999; 18: 57–78
29.
go back to reference Orme BK. Hierarchical Bayes: why all the attention? Sequim (WA): Sawtooth Software, Inc., 2000 Orme BK. Hierarchical Bayes: why all the attention? Sequim (WA): Sawtooth Software, Inc., 2000
30.
go back to reference Byrne CM, Solomon MJ, Young JM, et al. Patient preferences between surgical and medical treatment in Crohn’s disease. Dis Colon Rectum 2007; 50(5): 586–97PubMedCrossRef Byrne CM, Solomon MJ, Young JM, et al. Patient preferences between surgical and medical treatment in Crohn’s disease. Dis Colon Rectum 2007; 50(5): 586–97PubMedCrossRef
31.
go back to reference Braddock III CH, Edwards KA, Hasenberg NM, et al. Informed decision making in outpatient practice: time to get back to basics. JAMA 1999; 282(24): 2313–20PubMedCrossRef Braddock III CH, Edwards KA, Hasenberg NM, et al. Informed decision making in outpatient practice: time to get back to basics. JAMA 1999; 282(24): 2313–20PubMedCrossRef
32.
go back to reference Braddock III CH, Fihn SD, Levinson W, et al. How doctors and patients discuss routine clinical decisions: informed decision making in the outpatient setting. J Gen Intern Med 1997; 12(6): 339–45PubMed Braddock III CH, Fihn SD, Levinson W, et al. How doctors and patients discuss routine clinical decisions: informed decision making in the outpatient setting. J Gen Intern Med 1997; 12(6): 339–45PubMed
33.
go back to reference Waitzkin H. Doctor-patient communication: clinical implications of social scientific research. JAMA 1984; 252(17): 2441–6PubMedCrossRef Waitzkin H. Doctor-patient communication: clinical implications of social scientific research. JAMA 1984; 252(17): 2441–6PubMedCrossRef
34.
go back to reference Montgomery AA, Fahey T. How do patients’ treatment preferences compare with those of clinicians? Qual Health Care 2001; 10Suppl. 1: i39–43PubMed Montgomery AA, Fahey T. How do patients’ treatment preferences compare with those of clinicians? Qual Health Care 2001; 10Suppl. 1: i39–43PubMed
35.
go back to reference Brazier M. Patient autonomy and consent to treatment: the role of the law? Leg Stud (Soc Leg Scholars) 1987; 7(2): 169–93CrossRef Brazier M. Patient autonomy and consent to treatment: the role of the law? Leg Stud (Soc Leg Scholars) 1987; 7(2): 169–93CrossRef
36.
go back to reference Quill TE, Brody H. Physician recommendations and patient autonomy: finding a balance between physician power and patient choice. Ann Intern Med 1996; 125(9): 763–9PubMed Quill TE, Brody H. Physician recommendations and patient autonomy: finding a balance between physician power and patient choice. Ann Intern Med 1996; 125(9): 763–9PubMed
37.
go back to reference Hickson GB, Clayton EW, Entman SS, et al. Obstetricians’ prior malpractice experience and patients’ satisfaction with care. JAMA 1994; 272(20): 1583–7PubMedCrossRef Hickson GB, Clayton EW, Entman SS, et al. Obstetricians’ prior malpractice experience and patients’ satisfaction with care. JAMA 1994; 272(20): 1583–7PubMedCrossRef
38.
go back to reference Gattellari M, Butow PN, Tattersall MH. Sharing decisions in cancer care. Soc Sci Med 2001; 52(12): 1865–78PubMedCrossRef Gattellari M, Butow PN, Tattersall MH. Sharing decisions in cancer care. Soc Sci Med 2001; 52(12): 1865–78PubMedCrossRef
39.
go back to reference Sewitch MJ, Abrahamowicz M, Barkun A, et al. Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol 2003; 98(7): 1535–44PubMedCrossRef Sewitch MJ, Abrahamowicz M, Barkun A, et al. Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol 2003; 98(7): 1535–44PubMedCrossRef
40.
go back to reference Towle A, Godolphin W. Framework for teaching and learning informed shared decision making. BMJ 1999; 319(7212): 766–71PubMedCrossRef Towle A, Godolphin W. Framework for teaching and learning informed shared decision making. BMJ 1999; 319(7212): 766–71PubMedCrossRef
41.
go back to reference Vermeire E, Hearnshaw H, Van Royen P, et al. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther 2001; 26(5): 331–42PubMedCrossRef Vermeire E, Hearnshaw H, Van Royen P, et al. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther 2001; 26(5): 331–42PubMedCrossRef
42.
go back to reference Brody DS, Miller SM, Lerman CE, et al. The relationship between patients’ satisfaction with their physicians and perceptions about interventions they desired and received. Med Care 1989; 27(11): 1027–35PubMedCrossRef Brody DS, Miller SM, Lerman CE, et al. The relationship between patients’ satisfaction with their physicians and perceptions about interventions they desired and received. Med Care 1989; 27(11): 1027–35PubMedCrossRef
43.
go back to reference Golin C, DiMatteo MR, Duan N, et al. Impoverished diabetic patients whose doctors facilitate their participation in medical decision making are more satisfied with their care. J Gen Intern Med 2002; 17(11): 866–75CrossRef Golin C, DiMatteo MR, Duan N, et al. Impoverished diabetic patients whose doctors facilitate their participation in medical decision making are more satisfied with their care. J Gen Intern Med 2002; 17(11): 866–75CrossRef
44.
go back to reference Sheridan SL, Harris RP, Woolf SH. Shared decision making about screening and chemoprevention: a suggested approach from the US Preventive Services Task Force. Am J Prev Med 2004; 26(1): 56–66PubMedCrossRef Sheridan SL, Harris RP, Woolf SH. Shared decision making about screening and chemoprevention: a suggested approach from the US Preventive Services Task Force. Am J Prev Med 2004; 26(1): 56–66PubMedCrossRef
45.
go back to reference Stewart M, Brown JB, Donner A, et al. The impact of patient-centered care on outcomes. J Fam Pract 2000; 49(9): 796–804PubMed Stewart M, Brown JB, Donner A, et al. The impact of patient-centered care on outcomes. J Fam Pract 2000; 49(9): 796–804PubMed
Metadata
Title
Assessing Drug Treatment Preferences of Patients with Crohn’s Disease
A Conjoint Analysis
Authors
Dr Gary R. Lichtenstein
Heidi C. Waters
Jenna Kelly
Susan S. McDonald
Elaine L. Zanutto
David Hendricks
Mirza I. Rahman
Publication date
01-06-2010
Publisher
Springer International Publishing
Published in
The Patient - Patient-Centered Outcomes Research / Issue 2/2010
Print ISSN: 1178-1653
Electronic ISSN: 1178-1661
DOI
https://doi.org/10.2165/11314880-000000000-00000

Other articles of this Issue 2/2010

The Patient - Patient-Centered Outcomes Research 2/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.